期刊
ALZHEIMERS & DEMENTIA
卷 15, 期 2, 页码 205-216出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2018.09.001
关键词
beta-amyloid; Positron emission tomography; Centiloid; CERAD; Thal; Alzheimer's disease neuropathologic changes; Neuropathology; Harmonization; Threshold; Pittsburgh compound-B
资金
- UCSF-National Institutes of Health [R01-AG045611, P01-AG1972403, P50-AG023501, R01-AG032306, K24 AG053435]
- Tau Consortium, Consortium for Frontotemporal Dementia Research
- John Douglas French Alzheimer's Foundation
- Alzheimer's Association [AARF-16-443577]
- UCD-National Institutes of Health [P30 AG010129, P01 AG012435, R01 AG021028, R01 AG031563]
- UC Berkeley-National Institute of Health [R01AG034570]
- Mayo-National Institutes of Health [R01 NS097495, U01 AG006786, P50 AG016574/P1, R01 AG011378, R01 AG041851, R01 AG054449]
- GHR Foundation
- Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation, Liston Award
- Elsie and Marvin Dekelboum Family Foundation
- Schuler Foundation
- NHMRC [1132604]
- UPitt: National Institute of Health [P50 AG005133, RF1 AG025516, P01 AG025204]
- AIBL-NHMRC Research Fellowship [1046471]
- National Health and Medical Research Council of Australia [1132604] Funding Source: NHMRC
Introduction: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [C-11]PIB-positron emission tomography ([C-11]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for A beta-PET quantification. Methods: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results: CL values increased with each CERAD neuritic plaque score increment (median -3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Ab phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion: Our study demonstrated the robustness of a multisite Centiloid [C-11]PIB-PET study and established a range of pathology-based CL thresholds. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据